NuCana (NCNA) Accumulated Expenses (2016 - 2025)
NuCana's (NCNA) quarterly Accumulated Expenses came in at $5.5 million in Q4 2025, down 24.69% year-on-year from $7.3 million in Q4 2024, and down 7.36% quarter-over-quarter from $6.0 million in Q3 2025.
NuCana (NCNA) Accumulated Expenses (2016 - 2025) Analysis & Trends
NuCana has disclosed Accumulated Expenses across 10 years of filings, most recently posting $5.5 million for Q4 2025.
- Accumulated Expenses for Q4 2025 came in at $5.5 million, down 24.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.5 million (down 24.69% YoY), and the FY2025 annual result was $5.5 million, down 25.05% from the prior year.
- Accumulated Expenses came in at $5.5 million for Q4 2025 at NuCana, down from $6.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $12.8 million in Q4 2021 to a low of $5.5 million in Q4 2025.
- The 5-year median for Accumulated Expenses is $9.1 million (2022), against an average of $9.1 million.
- Across the five-year window, Accumulated Expenses soared 84.73% in 2021 and tumbled 48.19% in 2025, its largest moves.
- NuCana's Accumulated Expenses stood at $12.8 million in 2021, then slipped by 8.49% to $11.7 million in 2022, then dropped by 5.42% to $11.1 million in 2023, then sank by 33.9% to $7.3 million in 2024, then decreased by 24.69% to $5.5 million in 2025.
- The last three Accumulated Expenses figures came in at $5.5 million (Q4 2025), $6.0 million (Q3 2025), and $6.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 6.32 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 7.33 Mn |
| Sep 30, 2024 | 11.31 Mn |
| Jun 30, 2024 | 12.19 Mn |
| Mar 31, 2024 | 10.52 Mn |
| Dec 31, 2023 | 11.10 Mn |
| Sep 30, 2023 | 8.04 Mn |
| Jun 30, 2023 | 6.74 Mn |
| Mar 31, 2023 | 7.81 Mn |
| Dec 31, 2022 | 11.73 Mn |
| Sep 30, 2022 | 11.14 Mn |
| Jun 30, 2022 | 10.08 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 12.82 Mn |
| Sep 30, 2021 | 10.77 Mn |
| Jun 30, 2021 | 7.99 Mn |
| Mar 31, 2021 | 7.01 Mn |